CYDY
vs
S&P 500
CYDY
S&P 500
Over the past 12 months, CYDY has significantly outperformed S&P 500, delivering a return of +139% compared to the S&P 500's +14% growth.
Stocks Performance
CYDY vs S&P 500
Performance Gap
CYDY vs S&P 500
Performance By Year
CYDY vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cytodyn Inc
Glance View
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. The company is headquartered in Vancouver Washington, Washington and currently employs 24 full-time employees. The company went IPO on 2005-11-17. The CCR5 receptor is a protein located on the surface of various cells including white blood cells and cancer cells. The CCR5 receptor is also the co-receptor needed for certain strains of human immunodeficiency virus (HIV) to infect healthy T-cells. The firm also completed a Phase IIb/III investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients. The firm is also conducting a Phase II clinical trial with leronlimab in metastatic Triple Negative Breast Cancer (mTNBC), a Phase II basket trial in solid tumor cancers (22 different cancer indications), Phase II investigative trial for post-acute sequelae of SARS COV-2, also known as COVID-19 long haulers, and a Phase II clinical trial for nonalcoholic steatohepatitis (NASH).